Theory Paper IIDrNB Cardiology – Theory Notes
APPROACH TO AN ELDERLY PATIENT WITH HYPERTENSION
IINTRODUCTION AND THE FRAILTY PARADIGM
- Definitions: Hypertension in older adults (chronologically defined as 65 years or older, and the “very old” as 80 years or older) is the leading modifiable driver of stroke, heart failure, atrial fibrillation, chronic kidney disease, and vascular dementia.
- Biological Age vs. Chronological Age: Contemporary guidelines (2024 ESC and 2023 ESH Guidelines) shift decision-making from chronological age alone to biological age, functional autonomy, and Frailty (quantified using tools such as the Clinical Frailty Scale [CFS 1 to 9]), balancing major cardiovascular event reduction against the iatrogenic hazards of orthostatic hypotension, injurious falls, syncope, and acute kidney injury.
IICORE PATHOPHYSIOLOGY IN THE AGING VASCULATURE
- Isolated Systolic Hypertension (ISH) and Loss of the Windkessel Effect:
- Structural Mechanism: Age-related fragmentation of medial elastin lamellae, replacement by stiff cross-linked collagen, and medial calcification markedly increase large-artery (aortic) stiffness and Pulse Wave Velocity (PWV), abolishing the physiological aortic Windkessel cushioning effect.
- Hemodynamic Consequence: The rigid aorta cannot distend during systole (augmenting peak Systolic Blood Pressure [SBP] via early return of reflected pulse waves in late systole rather than diastole) and fails to recoil during diastole (lowering Diastolic Blood Pressure [DBP]), resulting in a markedly widened Pulse Pressure (SBP minus DBP >=60 mmHg) and impaired diastolic coronary perfusion.
- The “Low-Renin, Salt-Sensitive” Volume Phenotype:
- Mechanism: Progressive nephrosclerosis and age-related decline in functioning nephrons and juxtaglomerular apparatus activity produce low plasma renin activity and impaired renal sodium excretion.
- Clinical Implication: Older patients exhibit pronounced salt sensitivity and respond most effectively to Calcium Channel Blockers (CCBs) and Thiazide/Thiazide-like diuretics, as well as dietary sodium restriction.
- Arterial Baroreceptor Reflex Blunting and Autonomic Dysregulation:
- Mechanism: Carotid sinus and aortic arch baroreceptor stiffening blunts reflex cardioacceleration and sympathetic vasoconstriction upon standing, predisposing older patients to Orthostatic Hypotension, Postprandial Hypotension, and marked 24-hour blood pressure variability.
IIICLINICAL EVALUATION AND BEDSIDE PITFALLS
- Mandatory Orthostatic Blood Pressure Screening (Class I): Blood pressure must be recorded in the seated/supine position and at 1 minute and 3 minutes after standing at baseline and after every dose titration. Orthostatic Hypotension is defined as a drop in SBP of 20 mmHg or greater or DBP of 10 mmHg or greater within 3 minutes of standing.
- Out-of-Office Confirmation (HBPM or ABPM — Class I): Because White-Coat Hypertension (common in older patients with ISH), nocturnal non-dipping, and autonomic hypotensive episodes are common in the elderly, Home (HBPM) or 24-hour Ambulatory Blood Pressure Monitoring (ABPM) is strongly recommended prior to escalating therapy.
- Pseudohypertension (Osler Maneuver) and the Auscultatory Gap:
- Pseudohypertension: Severe medial brachial artery calcification resists cuff compression, yielding falsely elevated cuff pressures relative to true intra-arterial pressure (suspected when high BP is accompanied by postural dizziness on minimal medication and absence of target-organ damage).
- Auscultatory Gap: Inflate the cuff at least 30 mmHg above the disappearance of the radial pulse (palpatory systolic pressure) to avoid underestimating SBP due to a silent auscultatory gap in severe ISH.
IVGUIDELINE-DIRECTED MANAGEMENT (ESC 2024 / ESH 2023 GUIDELINES)
| Patient Category & Functional Status | Office BP Threshold to Initiate Drug Therapy | Treated Systolic / Diastolic BP Target (ESC 2024 / ESH 2023) | Key Prescribing Strategy |
|---|---|---|---|
| Fit Older Adults (Age 65–79 yr, Non-Frail) | >= 140/90 mmHg (>=130/80 mmHg if high CVD risk) | SBP 120–129 mmHg (if well tolerated; otherwise 130–139 mmHg) and DBP 70–79 mmHg | Dual low-dose combination therapy (CCB + RAAS blocker or Diuretic); monitor eGFR/K+ |
| Fit “Very Old” Adults (Age >=80 yr, Non-Frail) | SBP >= 160 mmHg (consider at 140–159 mmHg if robust) | SBP 140–150 mmHg (ESH 2023) or 130–139 mmHg if tolerated (ESC 2024); avoid SBP <120 or DBP <70 mmHg | Often initiate monotherapy or low-dose dual therapy (“Start Low, Go Slow”) |
| Moderately-to-Severely Frail (CFS >=6), Institutionalized, or Orthostatic Hypotension | Individualized (typically SBP >= 160 mmHg) | Individualized symptom-safe target (<150 mmHg); Deprescribe / step-down if SBP <120–130 mmHg or falls occur | Monotherapy preferred; avoid polypharmacy (>3 drugs) |
- Pharmacological Drug Selection:
- First-Line Agents (Ideal for ISH & Low-Renin State): Long-acting Dihydropyridine Calcium Channel Blockers (Amlodipine 2.5 to 10 mg) and Thiazide-like Diuretics (Chlorthalidone 12.5 to 25 mg or Indapamide 1.5 mg SR)—both proven in landmark ISH trials (SHEP, Syst-Eur, HYVET)—combined with an ACE Inhibitor or ARB. (Monitor serum sodium closely on thiazides, as elderly patients—especially elderly women—are highly susceptible to thiazide-induced hyponatremia.)
- Agents to Avoid as Routine Antihypertensives: Alpha-1 Blockers (Prazosin, Doxazosin) and Centrally Acting Sympatholytics (Clonidine, Methyldopa) due to severe orthostatic hypotension, syncope, sedation, and hip-fracture falls (unless alpha-blockers are specifically required for benign prostatic hyperplasia, with bedtime dosing caution).
- The Diastolic Blood Pressure “J-Curve” Caveat: In older patients with wide-pulse-pressure ISH and obstructive coronary artery disease, lowering SBP aggressively can drive DBP below 60 to 70 mmHg; because the left ventricular subendocardium is perfused exclusively during diastole, excessive diastolic lowering can compromise coronary perfusion pressure and precipitate myocardial ischemia.
VLANDMARK CLINICAL TRIALS IN OLDER ADULTS
- SHEP (1991 — Chlorthalidone) and Syst-Eur (1997 — Nitrendipine) Trials: Definitively proved that treating Isolated Systolic Hypertension (SBP >=160 mmHg with DBP <90 mmHg) in patients aged 60 years or older reduced stroke by 36 to 42 percent, and SHEP roughly halved heart failure.
- HYVET Trial (NEJM 2008 — Hypertension in the Very Elderly Trial): Randomized 3,845 patients aged 80 years or older with sustained SBP >=160 mmHg to Indapamide SR (1.5 mg) +/- Perindopril versus placebo (targeting <150/80 mmHg). Halted early after demonstrating a 30 percent reduction in fatal/non-fatal stroke, a 64 percent reduction in heart failure, and a 21 percent reduction in all-cause mortality—proving that chronological age >=80 years is never a barrier to treatment in ambulatory seniors.
- SPRINT-Senior (JAMA 2016 — Age >=75 Years) and STEP Trial (NEJM 2021 — Age 60 to 80 Years):
- SPRINT-Senior (n = 2,636, age >=75 yr): Intensive BP lowering (target SBP <120 mmHg vs. <140 mmHg) reduced primary MACE by 34 percent and all-cause mortality by 33 percent, including in mildly frail community-dwelling seniors, without increasing injurious falls.
- STEP Trial (n = 8,511 Chinese patients aged 60–80 yr): Targeting SBP 110 to <130 mmHg versus 130 to <150 mmHg reduced composite cardiovascular events by 26 percent.
Key references
- McEvoy JW, McCarthy CP, Bruno RM, et al.: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension, European Heart Journal, 2024.
- Mancia G, Kreutz R, Brunström M, et al.: 2023 ESH Guidelines for the management of arterial hypertension, Journal of Hypertension, 2023.
- Beckett NS, Peters R, Fletcher AE, et al. (HYVET Study Group): Treatment of Hypertension in Patients 80 Years of Age or Older, New England Journal of Medicine, 2008.
- Williamson JD, Supiano MA, Applegate WB, et al. (SPRINT Research Group): Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >=75 Years, JAMA, 2016.
meritmedscript.comDr. Sidhartha Mullapudi
